Paper Details

  1. Home
  2. Paper Details

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Author: BehmB W, BickstonS J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Infliximab, adalimumab, and certolizumab pegol were effective in maintaining remission in Crohn's disease patients who responded to induction therapy. Infliximab also showed effectiveness in maintaining fistula healing.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Crohn's disease may be refractory to conventional treatments including corticosteroids and immunosuppressives. Recent studies suggest TNF-alpha blocking agents may be effective in maintaining remission in Crohn's disease. OBJECTIVES: To conduct a systematic review of the evidence for th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD006893

データ提供：米国国立医学図書館（NLM）

TNF-alpha Antibody for Crohn's Disease: A Desert Oasis of Relief

This research delves into the world of Crohn's disease, a chronic inflammatory condition that can cause significant discomfort and hardship. The study explores the potential of TNF-alpha blocking agents as a treatment for maintaining remission in patients with Crohn's disease. It's like finding a hidden oasis in the vast desert of inflammatory bowel diseases, offering hope for a more manageable and comfortable life for those affected.

Finding the Oasis: Effective Maintenance Treatment for Crohn's Disease

This research found that TNF-alpha blocking agents, such as infliximab, adalimumab, and certolizumab, are effective in maintaining remission in patients with Crohn's disease. This is like discovering a source of fresh water in the heart of the desert, providing a pathway to sustained relief and better quality of life. The study also found that these agents are generally well-tolerated, with similar adverse events compared to placebo. These results are encouraging for patients and healthcare providers alike, offering a beacon of hope in the management of Crohn's disease.

A Camel's Guide to Crohn's Management: Diet and Lifestyle

Maintaining a healthy diet, reducing stress, and managing emotional well-being are essential for managing Crohn's disease. It's like preparing for a long journey across the desert by carrying enough water and provisions. Consulting with a healthcare professional and following their personalized recommendations is crucial for maintaining long-term remission and preventing complications.

Dr.Camel's Conclusion

This research highlights the effectiveness of TNF-alpha blocking agents in maintaining remission in Crohn's disease. It underscores the importance of ongoing research and innovation in developing new and effective treatments for inflammatory bowel diseases. The findings provide a glimmer of hope for those navigating the challenging terrain of Crohn's disease, offering the promise of a more manageable future.

Date :
  1. Date Completed 2008-04-14
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

18254120

DOI: Digital Object Identifier

10.1002/14651858.CD006893

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.